February 14, 2019
|
April 29, 2019
|
October 8, 2019
|
July 6, 2018
|
August 1, 2019 (Final data collection date for primary outcome measure)
|
- Preclinical myocardial dysfunction [ Time Frame: At patient inclusion. ]
Incidence of patients with alteration in left ventricular myocardial strain (≤ 17% in absolute value).
- Left ventricular diastolic dysfunction [ Time Frame: At patient inclusion. ]
Incidence of patients with signs of diastolic dysfunction: average E/e' ratio (abnormal when > 14)
- Left ventricular hypertrophy [ Time Frame: At patient inclusion. ]
Incidence of patients with LV mass by linear measurements > 95 g/m2 if women and > 115 g/m2 if men.
- Left atrial dysfunction [ Time Frame: At patient inclusion. ]
Incidence of patients with abnormal reservoir strain (normal range: 38%-41%), or abnormal conduit strain (normal range: 21%-25%), or abnormal contractile strain (normal range: 16%-19%).
|
- Preclinical myocardial dysfunction [ Time Frame: At patient inclusion. ]
Alteration in left ventricular myocardial strain (≤ 17% in absolute value).
- Left ventricular diastolic dysfunction [ Time Frame: At patient inclusion. ]
Signs of diastolic dysfunction: average E/e' ratio (abnormal when > 14)
- Left ventricular hypertrophy [ Time Frame: At patient inclusion. ]
Defined as LV mass by linear measurements > 95 g/m2 in women and > 115 g/m2 in men.
- Left atrial function [ Time Frame: At patient inclusion. ]
Normal reservoir strain of 39% (range: 38%-41%), for conduit strain of 23% (range: 21%-25%), and for contractile strain of 17% (range: 16%-19%).
|
|
Not Provided
|
Not Provided
|
Not Provided
|
Not Provided
|
|
Preclinical Cardiomyopathy and Autonomic Function in Type 1 Diabetes
|
Preclinical Cardiomyopathy in Type 1 Diabetes: Correlation With Autonomic Dysfunction
|
Type 1 diabetes mellitus is a chronic autoimmune disease, associated with an increased risk of cardiovascular diseases. The development of cardiomyopathy in type 1 diabetes, independent of hypertension and coronary heart disease, is still controversial. A possible mechanism for diabetic cardiomyopathy is autonomic dysfunction. This study aims to evaluate cardiac function and structure, and to relate them with autonomic dysfunction in type 1 diabetes.
|
Not Provided
|
Observational
|
Observational Model: Case-Control Time Perspective: Cross-Sectional
|
Not Provided
|
Not Provided
|
Non-Probability Sample
|
Selection of patients from a tertiary hospital.
|
- Diabetes Mellitus, Type 1
- Diabetic Cardiomyopathies
- Autonomic Neuropathy, Diabetic
|
Not Provided
|
- Type 1 diabetic patients
Patients diagnosed with type 1 diabetes mellitus with criteria for cardiovascular autonomic neuropathy, asymptomatic, normotensive, with negative medical history of cardiovascular disease.
Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function.
- Control - Healthy subjects
Fifteen age- and sex-matched healthy control subjects, asymptomatic, normotensive, with negative medical history of cardiovascular disease.
Transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of heart structure and function.
|
Not Provided
|
|
Completed
|
80
|
50
|
September 1, 2019
|
August 1, 2019 (Final data collection date for primary outcome measure)
|
Inclusion Criteria:
Exclusion Criteria:
- hypertension
- coronary artery disease
- heart valve disease
- ventricular dysfunction
- radiotherapy or chemotherapy
- alcoholism
- limited acoustic window
|
Sexes Eligible for Study: |
All |
|
20 Years to 55 Years (Adult)
|
Yes
|
Contact information is only displayed when the study is recruiting subjects
|
Brazil
|
|
|
NCT03930004
|
HU-UFSC 2018
|
No
|
Studies a U.S. FDA-regulated Drug Product: |
No |
Studies a U.S. FDA-regulated Device Product: |
No |
|
|
Roberto Léo da Silva, Instituto de Cardiologia de Santa Catarina
|
Roberto Léo da Silva
|
Not Provided
|
Study Chair: |
Thais R Weber, MD |
HU/UFSC |
|
Instituto de Cardiologia de Santa Catarina
|
October 2019
|